Transcatheter aortic valve implantation (TAVI) has become an established treatment for severe aortic stenosis across an expanding risk spectrum. As indications extend to younger and lower-risk patients, post-treatment complications with implications for survival, quality of life, and valve durability require attention.

Despite substantial advances in treatment and preventive medicine, heart disease remains the leading cause of morbidity and mortality worldwide. While traditional risk factors have been identified, emerging research continues to underscore the importance of social interactions.

Thoracic endovascular aortic repair (TEVAR) is first-line therapy for most descending thoracic aortic pathologies, yet it is performed in patients with a heavy burden of coronary disease, hypertension and limited cardiac reserve, and its cardiac complications remain underemphasized relative to neurological and device-related events.

Microplastics and nanoplastics (MPs/NPs) are emerging environmental contaminants widely detected in food, drinking water, and human biological tissues. As human exposure continues to increase, accumulating evidence suggests that these particles may represent an emerging cardiovascular risk factor by inducing oxidative stress, chronic inflammation, endothelial dysfunction, lipid dysregulation, and other mechanisms that promote atherosclerosis.

Hypertension is a major contributor to cardiovascular morbidity and mortality. Given the suboptimal control rates with conventional antihypertensive medication, novel approaches are warranted. In the era of precision medicine, integrating hypertension genomics into diagnostic and therapeutic approaches may greatly advance hypertension management.

Pregnancy imposes a sustained hemodynamic load that can unmask latent cardiovascular vulnerability, yet distinguishing physiological adaptation from early maladaptive remodeling remains difficult with conventional echocardiography.

Left bundle branch area pacing (LBBAP) resynchronizes the left ventricle through the conduction system rather than through a coronary sinus lead, and is increasingly used as an alternative to biventricular pacing (BVP) for cardiac resynchronization therapy (CRT) in heart failure with reduced ejection fraction.

Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by raised levels of low-density lipoprotein cholesterol (LDL-C) and premature cardiovascular disease (CVD), with a prevalence of 1 in 300, which can be successfully treated. These features make it amenable for large-scale screening.

Heart failure (HF) is one of the most urgent unmet challenges in cardiovascular medicine. Despite advances in guideline-directed medical therapy (GDMT), substantial morbidity and mortality remain high in patients with advanced disease. This suggests a need for disease-modifying interventions that address underlying biological mechanisms.

Transcatheter aortic valve replacement (TAVR) is rapidly evolving to become the standard of care for aortic stenosis (AS) patients, as opposed to open-heart surgery. The emergence of new commercial TAVR devices, as well as technological advancements in AS diagnosis and procedural planning, combat post-TAVR complications but pose new challenges with patient selection and optimal timing of valve replacement. Computational modeling is a powerful tool that may help streamline solutions for heart teams facing these complexities.

Hypertensive disorders of pregnancy portend future cardiovascular risk and warrant implementation of evidence-based, preventive strategies. Lactation is an underrecognized, time-sensitive health behavior that improves cardiovascular outcomes across the life course.

Acute coronary syndrome (ACS) remains a leading cause of morbidity and mortality worldwide. Sex- and gender-related differences in ACS persist and encompass risk profiles, clinical presentation, management, and outcomes.

Transcatheter aortic valve implantation (TAVI) has expanded from a treatment for inoperable and high-risk aortic stenosis to an established therapeutic option for selected patients at low surgical risk. This review focuses on the outcomes of major trials comparing TAVI to traditional surgical aortic valve replacement (SAVR), highlighting outcomes and potential complications when considering lifetime valve management as we move into the younger population. A literature search of PubMed using terms such as 'transcatheter aortic valve replacement' and 'low surgical risk' was used to identify relevant publications from within the last 10 years. Recent randomized trials and follow-up studies suggest that, in appropriately selected low-risk patients, TAVI and SAVR provide broadly comparable mid-term outcomes for cardiovascular mortality, stroke, and valve re-intervention. However, important differences remain. TAVI is consistently associated with lower rates of new-onset atrial fibrillation but higher rates of permanent pacemaker implantation and paravalvular aortic regurgitation. As TAVI moves into younger and asymptomatic populations, unresolved questions remain around valve durability, coronary access, redo strategies, and lifetime valve management, highlighting the central role of multidisciplinary heart-team assessment in selecting the optimal lifetime therapeutic strategy.